




2026 Comprehensive Product Performance Package (“CPPP”)

The CPPP includes the Performance Test and an assessment of accumulation product performance.

Composition of Australia's superannuation system

Australians hold close to \$4.8 trillion in super, including \$3.4 trillion in APRA-regulated funds. The CPPP (covering 83% of the accumulation phase) provides information on the Performance Test alongside broader insights through additional metrics.



*Other includes exempt public sector schemes, balance of life office statutory funds and defined benefit funds.

TDP = trustee-directed product. EDP = externally-directed product. Refer to the 2026 CPPP insights paper for definitions of key terms.

Scope of the CPPP

The CPPP covers both MySuper and Choice products mainly focusing on products where the trustee is responsible for the investment strategy.



The Performance Test and the 2026 Outcomes

12 products failed the Performance Test in 2026, largely driven by poorer investment performance.

The Performance Test has two parts



1. Investment performance

How well investments performed against their strategic benchmarks



2. Admin fees and costs

How fees and costs compare to similar products



12

products failed

in 2026



~71.3k

member accounts affected

broadly in line with the last three years



Up from 7

products in 2025

Products assessed in 2026



547

products assessed

50

MySuper

356

Non-platform TDP

141

Platform TDP

Where failures occurred in 2026



Failures remain predominantly in platform products



What happens if products fail?

Products that fail for the first time must notify members of their underperformance.

Products that fail for two or more consecutive years can no longer be offered to new members.


Looking beyond the Performance Test

The CPPP combines multiple performance measures and time horizons to provide a broader assessment of product performance.

The CPPP Metric – assessing investment performance

The CPPP metric is a composite measure consisting of three investment metrics.

Each metric provides a different lens on investment performance, and when combined gives a broader view of a product's strengths and weaknesses.



What does the CPPP provide?

The CPPP allows comparison of how investment options are trending over time and across multiple investment performance and fees and costs metrics.

Investment Performance in 2026

Over the longer term, platform TDPs and non-platform EDPs have higher rates of underperformance against the CPPP metric than other product types.



% of member assets in significantly underperforming products

Shorter periods show recent performance; longer periods show persistence of performance delivered

Platform TDPs (\$21 billion) represent less than 5% of the broader platform sector which exceeds \$450 billion in assets.

It is important to note that some underperforming products as per the CPPP metric may have tax benefits, capital guarantees or other features that may offer value to some members.

Product Type	5 Year	7 Year	10 Year
MySuper	8%	7%	6%
Non-Platform TDP	15%	10%	9%
Platform TDP	18%	14%	22%
Non-Platform EDP	16%	19%	18%



What this means?


While performance can change from year to year, underperformance over longer periods may have a greater impact on members’ pre-retirement savings. Trustees should consider both recent performance and whether underperformance is persisting over time.

Administration fees and costs in 2026

Fees continue to decline at varying rates across products, though platform products remain materially more expensive.

Median administration fees and costs for \$50,000 account balance

This does not include fees for member-initiated activities, such as personal financial advice



Declining fees and costs

Superannuation fees and costs have declined steadily.



Fee gaps remain across products

Platform TDPs had the largest reductions, although remain materially more expensive than MySuper and Non-Platform TDPs.



Expensive products still remain

Smaller retail funds under \$10 billion are more typically associated with higher fees.



What this means?

Lower administration fees continue to support higher net returns for members across the industry. However, trustees need to strike an appropriate balance between competitive fees and investing in their operations to effectively manage current and emerging risks.

Fees and costs vary across account balances


Administration fees account for smaller proportions of pre-retirement savings as balances increase.

Products such as MySuper and Non-Platform TDPs offer lower fees and deliver competitive investment outcomes.

While Platform TDPs are more expensive, trustees for these products typically emphasise the ability of members to exert a greater level of control over their superannuation.

It is important that members carefully consider their individual circumstances and all relevant trade-offs – including performance track record, diversification, administration fees, and other costs (such as member-directed personal financial advice).

Administration fees and costs by account balance



At a \$100,000 balance:

\$431

Platform TDP fee

\$174

MySuper fee

+\$257
(2.5x higher)




What this means?

Members with low balances (e.g. \$10k or \$25k) can face higher administration fees as a proportion of their balances. Trustees should consider the impact of flat dollar administration fees on these members, particularly where there are no minimum balance requirements.

Net returns for members in MySuper products

There are significantly fewer lower-performing products since the introduction of the Performance Test - but trustee's investment performance remains critically important.



**What this means?**

Pre-retirement savings continue to grow with the gap between higher and lower-performing products narrowing. However, there is still scope for trustees to improve outcomes for their members.



Important information

This document should be read in conjunction with the other documents comprising the 2026 CPPP. Attention should be given to the 'APRA Performance Test Disclaimer' set out in the statistical publication and other important notices contained in the document.

The information contained in this document is general in nature and does not take into account the particular investment objectives or financial situation of any person. It does not constitute, and should not be relied on as, financial or investment advice or recommendations (express or implied) and is not an invitation to buy or sell any Listed Shares, Insurance, Superannuation, Investment and or financial product or service. No decision should be made on the basis of this document without first seeking expert financial advice. Any predictions or views contained in this presentation are those of the Australian Prudential Regulation Authority (APRA) (ABN 79 635 582 658). APRA does not represent or guarantee that the information is accurate or free from errors or omissions and APRA disclaims any duty of care in relation to the information and liability for any loss resulting from reliance on the information in making investment decisions.